About Us
Established in 1998, went public in May 2012, Dongcheng Biochemicals Co.,Ltd has developed into an enterprise group which combines ……
NEWS
Dongcheng Pharmaceutical has continuously increased its investment in scientific research and is committed to independent innovation.
Products
Dongcheng Pharmaceutical has continuously increased its investment in scientific research and is committed to independent innovation.
Branch
China's radiopharmaceutical industry is still in its infancy. In 2013, the output value of radio medicines nationwide was 2 billion yuan,
Service and Support
DCB now is one of the biggest biochemical API manufacturers in China, With leading production technology, reliable product quality and excellent international qualification background,
Investor Relations
Care for life with sincerity, Continuous innovation, striving for perfection! In the future, DCB will carry on the mission of serving human health,
★ YEAR 2017 January The company plans to acquire Nanjing Andi Electronics Zhengye Research and Development Co., Ltd. Through this acquisition, the company will further improve the industrial layout of radionuclides and become a supplier of complete nuclear medicine and nuclear medicine solutions, greatly consolidating the company. Leading position in the field of nuclear medicine YEAR 2016 August The company has invested RMB 65 million to control Yitai Pharmaceuticals, and has deployed 188[ReRe] etidronate injection frontier products for nuclear medicine. The company invested RMB 315 million to hold Thailand Zhongtai Bio to achieve low-cost procurement of raw materials and global collaboration March The company spent US$70 million to successfully acquire GMS (China), a founding company of domestic diagnostic radiopharmaceutical preparations, and completed the company’s nuclear chemical's entire industrial chain layout from diagnosis to treatment. YEAR 2015 October The company invested RMB 750 million to control the domestic No. 1 producer of therapeutic radionuclides, Chengdu Yunke Pharmaceutical, taking a crucial step in the advancement of nuclear medicine. YEAR 2014 June The company officially changed its name to “Yantai Dongcheng Pharmaceutical Group Co., Ltd.,” which indicates that the company has basically completed the “change from a single product of raw material medicines to the development of raw material medicines and preparations, focusing on development and group development”. YEAR 2013 September The company invested 85 million yuan in the construction of R&D and quality inspection building, equipped with international high-end scientific research equipment. May The company spent RMB 167 million to complete the acquisition of Yantai Ocean Pharmaceuticals March The company invested 470 million yuan to raise investment projects "Dongcheng Biopharm Industrial Park" officially started construction YEAR 2012 May 25 Shenzhen Stock Exchange successfully listed May 14 Online road show May Shenzhen, Shanghai and Beijing Road Show May 3 Received approval from the Securities Regulatory Commission for approval of Dongcheng IPO January 6 Dongcheng Pharmaceuticals' listing application is reviewed by the Issuing Committee YEAR 2008 — YEAR 2012 Dongcheng Pharmaceutical Listed Preparation Work January 9 Dongcheng Pharmaceutical Group (Formerly Dongcheng Biochemical) Co., Ltd. Officially Unveiled YEAR 2007 December 19 Dongcheng Pharmaceutical Group (Formerly Dongcheng Biochemical) Co., Ltd. was founded and officially launched its listing YEAR 2006 Dongyuan Biological Engineering Co., Ltd., a wholly-owned subsidiary, started construction in Funan County, Shandong Province, completing the layout of the upstream of the industrial chain. YEAR 2002 The company merged Yantai North Pharmaceutical Co., Ltd. and the industrial chain extended to the downstream formulation industry. YEAR 2000 The company became the first domestic biochemical raw material medicine company to pass the GMP certification of the State Food and Drug Administration YEAR 1999 The company was built and the first heparin sodium drug product was put into production YEAR 1998 Dongcheng Pharmaceutical Co., Ltd. (formerly Tung Shing Biochemical Co., Ltd.) started construction and kicked off the rapid rise.
